International Journal of Cancer Management

Published by: Kowsar

The Relationship of Fas Promoter Polymorphisms and Breast Cancer Risk in North-West of Iran: A Haplotype and in Silico Analysis

Narges Dastmalchi 1 , Reza Safaralizadeh 1 , Mohammad Ali Hosseinpour Feizi 1 , * and Nasser Pouladi 2
Authors Information
1 Animal Biology Department, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran
2 Cellular and Molecular Biology Department, Faculty of Biology, Azarbaijan Shahid Madani University, Tabriz, Iran
Article information
  • International Journal of Cancer Management: September 2017, 10 (9); e10528
  • Published Online: September 30, 2017
  • Article Type: Research Article
  • Received: January 16, 2017
  • Revised: March 15, 2017
  • Accepted: August 26, 2017
  • DOI: 10.5812/ijcm.10528

To Cite: Dastmalchi N, Safaralizadeh R, Hosseinpour Feizi M A, Pouladi N. The Relationship of Fas Promoter Polymorphisms and Breast Cancer Risk in North-West of Iran: A Haplotype and in Silico Analysis, Int J Cancer Manag. 2017 ; 10(9):e10528. doi: 10.5812/ijcm.10528.

Abstract
Copyright © 2017, Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnotes
References
  • 1. Babu GR, Samari G, Cohen SP, Mahapatra T, Wahbe RM, Mermash S, et al. Breast cancer screening among females in Iran and recommendations for improved practice: a review. Asian Pac J Cancer Prev. 2011; 12(7): 1647-55[PubMed]
  • 2. Hashemi M, Fazaeli A, Ghavami S, Eskandari-Nasab E, Arbabi F, Mashhadi MA, et al. Functional polymorphisms of FAS and FASL gene and risk of breast cancer - pilot study of 134 cases. PLoS One. 2013; 8(1): 53075[DOI][PubMed]
  • 3. Xu Y, Deng Q, He B, Pan Y, Li R, Gao T, et al. The diplotype Fas -1377A/-670G as a genetic marker to predict a lower risk of breast cancer in Chinese women. Tumour Biol. 2014; 35(9): 9147-61[DOI][PubMed]
  • 4. Stecklein SR, Jensen RA, Pal A. Genetic and epigenetic signatures of breast cancer subtypes. Front Biosci (Elite Ed). 2012; 4: 934-49[PubMed]
  • 5. Zhang B, Sun T, Xue L, Han X, Zhang B, Lu N, et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis. 2007; 28(5): 1067-73[DOI][PubMed]
  • 6. Nichols KE, Malkin D, Garber JE, Fraumeni JJ, Li FP. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev. 2001; 10(2): 83-7[PubMed]
  • 7. Dalan AB, Timirci-Kahraman O, Turan S, Kafadar AM, Yaylim I, Ergen A, et al. Association between FAS and FASL genetic variants and risk of primary brain tumor. Int J Neurosci. 2014; 124(6): 443-9[DOI][PubMed]
  • 8. Zhang Z, Wang LE, Sturgis EM, El-Naggar AK, Hong WK, Amos CI, et al. Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res. 2006; 12(18): 5596-602[DOI][PubMed]
  • 9. Zhang Z, Xue H, Gong W, Wang M, Yuan L, Han S, et al. FAS promoter polymorphisms and cancer risk: a meta-analysis based on 34 case-control studies. Carcinogenesis. 2009; 30(3): 487-93[DOI][PubMed]
  • 10. Kim R, Emi M, Tanabe K, Uchida Y, Toge T. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer. 2004; 100(11): 2281-91[DOI][PubMed]
  • 11. Zhou RM, Wang N, Chen ZF, Duan YN, Sun DL, Li Y. Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma. J Gastroenterol Hepatol. 2010; 25(3): 555-61[DOI][PubMed]
  • 12. Wang M, Wu D, Tan M, Gong W, Xue H, Shen H, et al. FAS and FAS ligand polymorphisms in the promoter regions and risk of gastric cancer in Southern China. Biochem Genet. 2009; 47(7-8): 559-68[DOI][PubMed]
  • 13. Sung WW, Wang YC, Cheng YW, Lee MC, Yeh KT, Wang L, et al. A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer. Clin Cancer Res. 2011; 17(18): 5991-9[DOI][PubMed]
  • 14. Valibeigi B, Amirghofran Z, Golmoghaddam H, Hajihosseini R, Kamazani FM. Fas gene variants in childhood acute lymphoblastic leukemia and association with prognosis. Pathol Oncol Res. 2014; 20(2): 367-74[DOI][PubMed]
  • 15. Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL, et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res. 2003; 63(15): 4327-30[PubMed]
  • 16. Crew KD, Gammon MD, Terry MB, Zhang FF, Agrawal M, Eng SM, et al. Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis. 2007; 28(12): 2548-51[DOI][PubMed]
  • 17. Bartlett JMS. Ovarian cancer: Methods and protocols. 2000;
  • 18. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. Breast: AJCC cancer staging manual. 2010;
  • 19. Li X, Ding X, Chu B, Ding G, Gu S, Qian L, et al. Molecular authentication of Alisma orientale by PCR-RFLP and ARMS. Planta Med. 2007; 73(1): 67-70[DOI][PubMed]
  • 20. Sun T, Miao X, Zhang X, Tan W, Xiong P, Lin D. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst. 2004; 96(13): 1030-6[PubMed]
  • 21. Dufournet C, Uzan C, Fauvet R, Cortez A, Siffroi JP, Darai E. Expression of apoptosis-related proteins in peritoneal, ovarian and colorectal endometriosis. J Reprod Immunol. 2006; 70(1-2): 151-62[DOI][PubMed]
  • 22. Farre L, Bittencourt AL, Silva-Santos G, Almeida A, Silva AC, Decanine D, et al. Fas 670 promoter polymorphism is associated to susceptibility, clinical presentation, and survival in adult T cell leukemia. J Leukoc Biol. 2008; 83(1): 220-2[DOI][PubMed]
  • 23. Li C, Wu W, Liu J, Qian L, Li A, Yang K, et al. Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: a case-control analysis. Pharmacogenet Genomics. 2006; 16(4): 245-51[DOI][PubMed]
  • 24. Park JY, Lee WK, Jung DK, Choi JE, Park TI, Lee EB, et al. Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer. Clin Cancer Res. 2009; 15(5): 1794-800[DOI][PubMed]
  • 25. Gaddipati H, Herlyn M. Association of polymorphisms of FAS-1377, FAS-670, and FASL-844 genes with risk factors for cutaneous malignant melanoma. Cancer J. 2007; 13(4): 226-8[DOI][PubMed]
  • 26. Yildir S, Sezgin M, Barlas IO, Turkoz G, Ankarali HC, Sahin G, et al. Relation of the Fas and FasL gene polymorphisms with susceptibility to and severity of rheumatoid arthritis. Rheumatol Int. 2013; 33(10): 2637-45[DOI][PubMed]
  • 27. Lima L, Morais A, Lobo F, Calais-da-Silva FM, Calais-da-Silva FE, Medeiros R. Association between FAS polymorphism and prostate cancer development. Prostate Cancer Prostatic Dis. 2008; 11(1): 94-8[DOI][PubMed]
  • 28. Xu Y, He B, Li R, Pan Y, Gao T, Deng Q, et al. Association of the polymorphisms in the Fas/FasL promoter regions with cancer susceptibility: a systematic review and meta-analysis of 52 studies. PLoS One. 2014; 9(3): 90090[DOI][PubMed]
  • 29. Mohammadi A, Tajik N, Shah-Hosseini A, Alavian SM, Sharifi Z, Jarahi L. FAS and FAS-Ligand Promoter Polymorphisms in Hepatitis B Virus Infection. Hepat Mon. 2015; 15(10): 26490[DOI][PubMed]
  • 30. Han W, Zhou Y, Zhong R, Wu C, Song R, Liu L, et al. Functional polymorphisms in FAS/FASL system increase the risk of neuroblastoma in Chinese population. PLoS One. 2013; 8(8): 71656[DOI][PubMed]
  • 31. Zeng J, Fang Y, Li P. FAS-1377 A/G polymorphism in breast cancer: a meta-analysis. Tumour Biol. 2014; 35(3): 2575-81[DOI][PubMed]
  • 32. Li K, Li W, Zou H, Zhao L. Association between FAS 1377G>A polymorphism and breast cancer susceptibility: a meta-analysis. Tumour Biol. 2014; 35(1): 351-6[DOI][PubMed]
  • 33. Verim L, Timirci-Kahraman O, Akbulut H, Akbas A, Ozturk T, Turan S, et al. Functional genetic variants in apoptosis-associated FAS and FASL genes and risk of bladder cancer in a Turkish population. In Vivo. 2014; 28(3): 397-402[PubMed]
  • 34. Nadeau JH. Single nucleotide polymorphisms: tackling complexity. Nature. 2002; 420(6915): 517-8[DOI][PubMed]
  • 35. Kim JB, Sarraf P, Wright M, Yao KM, Mueller E, Solanes G, et al. Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. J Clin Invest. 1998; 101(1): 1-9[DOI][PubMed]
  • 36. Koster R, Timmer-Bosscha H, Bischoff R, Gietema JA, de Jong S. Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway. Cell Death Dis. 2011; 2: 148[DOI][PubMed]
  • 37. Aftabi Y, Colagar AH, Mehrnejad F. An in silico approach to investigate the source of the controversial interpretations about the phenotypic results of the human AhR-gene G1661A polymorphism. J Theor Biol. 2016; 393: 1-15[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments